Last update March 3, 2022
Very Low Risk
Montelukast is a selective leukotriene receptor antagonist with actions and uses similar to those of zafirlukast. Used in the management of asthma and allergic rhinitis. Oral administration once daily.
Pharmacokinetic data (moderately high molecular weight, very high protein-binding capacity and low pKa) explain an observed very low excretion into breastmilk. (Datta 2016)
A drug of the same group and similar effect, Zafirlukast, is also excreted into breastmilk in non-significant amounts.
It is a licensed medication to be used in infants from 6 months of age on. Indeed, it has been used as early as 3 months of age with the same tolerance observed in older children.(Kearns 2008, Knorr 2006, Migoya 2004)
Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Chambers 2021, Middleton 2020, Briggs 2015, Nice 2004)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.